Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Sham Mailankody; Jeffrey V. Matous; Michaela Liedtke; Surbhi Sidana; Shahbaz Malik; Rajneesh Nath; Olalekan O. Oluwole; Erin E. Karski; Wade Lovelace; Xiangdong Zhou; Srinand Nandakumar; Arun Balakumaran; Parameswaran Hari

doi:10.1182/BLOOD-2020-140641

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Sham Mailankody
, Jeffrey V. Matous
, Michaela Liedtke
, Surbhi Sidana
, Shahbaz Malik
, Rajneesh Nath
, Olalekan O. Oluwole
, Erin E. Karski
, Wade Lovelace
, Xiangdong Zhou
, Srinand Nandakumar
, Arun Balakumaran
, Parameswaran Hari

Memorial Sloan-Kettering Cancer Center
Sarah Cannon Research Institute
Stanford University
Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
University of Texas MD Anderson Cancer Center
Vanderbilt University
Allogene Therapeutics, South San Francisco, CA
Medical College of Wisconsin

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	136
DOIs	https://doi.org/10.1182/BLOOD-2020-140641
State	Published - Nov 5 2020
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1182/BLOOD-2020-140641License: Unspecified

Cite this

Mailankody, S., Matous, J. V., Liedtke, M., Sidana, S., Malik, S., Nath, R., Oluwole, O. O., Karski, E. E., Lovelace, W., Zhou, X., Nandakumar, S., Balakumaran, A., & Hari, P. (2020). Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. Blood, 136. https://doi.org/10.1182/BLOOD-2020-140641

@article{9a80bc27f4364bdfa238b1be285fbb05,

title = "Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma",

author = "Sham Mailankody and Matous, \{Jeffrey V.\} and Michaela Liedtke and Surbhi Sidana and Shahbaz Malik and Rajneesh Nath and Oluwole, \{Olalekan O.\} and Karski, \{Erin E.\} and Wade Lovelace and Xiangdong Zhou and Srinand Nandakumar and Arun Balakumaran and Parameswaran Hari",

note = "Oral and Poster Abstracts Oral 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data multiple myeloma, Biological, Diseases, Therapies, CAR-Ts, Plasma Cell Disorders, Lymphoid Malignancies Sham Mailankody, MBBS 1, Jeffrey V. Matous, MD 2, Michaela Liedtke, MD 3, Surbhi Sidana, MD 4, Shahbaz Malik, MD 5 *, Rajneesh Nath, MD 6, Olalekan O.",

year = "2020",

month = nov,

day = "5",

doi = "10.1182/BLOOD-2020-140641",

language = "American English",

volume = "136",

journal = "Blood",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

AU - Mailankody, Sham

AU - Matous, Jeffrey V.

AU - Liedtke, Michaela

AU - Sidana, Surbhi

AU - Malik, Shahbaz

AU - Nath, Rajneesh

AU - Oluwole, Olalekan O.

AU - Karski, Erin E.

AU - Lovelace, Wade

AU - Zhou, Xiangdong

AU - Nandakumar, Srinand

AU - Balakumaran, Arun

AU - Hari, Parameswaran

N1 - Oral and Poster Abstracts Oral 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data multiple myeloma, Biological, Diseases, Therapies, CAR-Ts, Plasma Cell Disorders, Lymphoid Malignancies Sham Mailankody, MBBS 1, Jeffrey V. Matous, MD 2, Michaela Liedtke, MD 3, Surbhi Sidana, MD 4, Shahbaz Malik, MD 5 *, Rajneesh Nath, MD 6, Olalekan O.

PY - 2020/11/5

Y1 - 2020/11/5

UR - https://ash.confex.com/ash/2020/webprogram/Paper140641.html

U2 - 10.1182/BLOOD-2020-140641

DO - 10.1182/BLOOD-2020-140641

M3 - Article

VL - 136

JO - Blood

JF - Blood

ER -

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Disciplines

Access to Document

Other files and links

Cite this